These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 26869327)

  • 1. Increased Reach of Genetic Cancer Risk Assessment as a Tool for Precision Management of Hereditary Breast Cancer.
    Blazer KR; Slavin T; Weitzel JN
    JAMA Oncol; 2016 Jun; 2(6):723-4. PubMed ID: 26869327
    [No Abstract]   [Full Text] [Related]  

  • 2. Precision medicine meets public health: population screening for BRCA1 and BRCA2.
    Levy-Lahad E; Lahad A; King MC
    J Natl Cancer Inst; 2015 Jan; 107(1):420. PubMed ID: 25550384
    [No Abstract]   [Full Text] [Related]  

  • 3. Treating the genetic make-up of breast cancer: a new fashion?
    Linn SC; Jonkers J
    Expert Rev Anticancer Ther; 2007 Aug; 7(8):1065-7. PubMed ID: 17725409
    [No Abstract]   [Full Text] [Related]  

  • 4. BRCA1 and BRCA2 Testing Among Young Breast Cancer Survivors.
    Kehl KL; Giordano SH
    JAMA Oncol; 2016 May; 2(5):688-9. PubMed ID: 27244682
    [No Abstract]   [Full Text] [Related]  

  • 5. Breast-cancer risk in BRCA-mutation-negative women from BRCA-mutation-positive families.
    Katki HA; Gail MH; Greene MH
    Lancet Oncol; 2007 Dec; 8(12):1042-1043. PubMed ID: 18054868
    [No Abstract]   [Full Text] [Related]  

  • 6. Genetic testing in women with breast cancer: implications for treatment.
    Paterson R; Phillips KA
    Expert Rev Anticancer Ther; 2017 Nov; 17(11):991-1002. PubMed ID: 28853307
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Breast cancer screening in BRCA1 and BRCA2 mutation carriers after risk reducing salpingo-oophorectomy.
    Fakkert IE; Jansen L; Meijer K; Kok T; Oosterwijk JC; Mourits MJ; de Bock GH
    Breast Cancer Res Treat; 2011 Aug; 129(1):157-64. PubMed ID: 21373873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. BRCA to the future: towards best testing practice in the era of personalised healthcare.
    Capoluongo E
    Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S1-2. PubMed ID: 27514838
    [No Abstract]   [Full Text] [Related]  

  • 9. Screening mammography and risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a case-control study.
    Narod SA; Lubinski J; Ghadirian P; Lynch HT; Moller P; Foulkes WD; Rosen B; Kim-Sing C; Isaacs C; Domchek S; Sun P;
    Lancet Oncol; 2006 May; 7(5):402-6. PubMed ID: 16648044
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetic Testing After Previous BRCA Testing: A Case Study.
    Ward M
    Clin J Oncol Nurs; 2016 Dec; 20(6):660-663. PubMed ID: 27857264
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical implications of hereditary breast cancer.
    Quan ML; Petrek JA
    Adv Surg; 2003; 37():197-212. PubMed ID: 12953634
    [No Abstract]   [Full Text] [Related]  

  • 12. [Peculiarities of diagnosis, treatment and prevention of hereditary cancer of the breast and ovary. Clinical and genetic screening among BRCA1/2 mutation carriers and individuals with high family risk of cancer].
    Rumiantseva UV; Rumiantsev PO; Kiseleva MV
    Vopr Onkol; 2008; 54(3):251-9. PubMed ID: 18652227
    [No Abstract]   [Full Text] [Related]  

  • 13. BRCA Testing Dichotomy in Saudi Arabia.
    Abusanad A
    J Glob Oncol; 2019 Jan; 5():1-2. PubMed ID: 30707664
    [No Abstract]   [Full Text] [Related]  

  • 14. BRCA screening.
    Med Lett Drugs Ther; 2007 Nov; 49(1274):93-4. PubMed ID: 18007543
    [No Abstract]   [Full Text] [Related]  

  • 15. High risk of contralateral breast carcinoma in women with hereditary/familial non-BRCA1/BRCA2 breast carcinoma.
    Shahedi K; Emanuelsson M; Wiklund F; Gronberg H
    Cancer; 2006 Mar; 106(6):1237-42. PubMed ID: 16475207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mammography screening and the risk of breast cancer in BRCA1 and BRCA2 mutation carriers: a prospective study.
    Giannakeas V; Lubinski J; Gronwald J; Moller P; Armel S; Lynch HT; Foulkes WD; Kim-Sing C; Singer C; Neuhausen SL; Friedman E; Tung N; Senter L; Sun P; Narod SA
    Breast Cancer Res Treat; 2014 Aug; 147(1):113-8. PubMed ID: 25082516
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bar code screening on combed DNA for large rearrangements of the BRCA1 and BRCA2 genes in French breast cancer families.
    Gad S; Klinger M; Caux-Moncoutier V; Pages-Berhouet S; Gauthier-Villars M; Coupier I; Bensimon A; Aurias A; Stoppa-Lyonnet D
    J Med Genet; 2002 Nov; 39(11):817-21. PubMed ID: 12414821
    [No Abstract]   [Full Text] [Related]  

  • 18. Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2.
    Domchek SM; Gaudet MM; Stopfer JE; Fleischaut MH; Powers J; Kauff N; Offit K; Nathanson KL; Robson M
    Breast Cancer Res Treat; 2010 Jan; 119(2):409-14. PubMed ID: 19885732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
    Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
    Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Screening of over 1000 Indian patients with breast and/or ovarian cancer with a multi-gene panel: prevalence of BRCA1/2 and non-BRCA mutations.
    Singh J; Thota N; Singh S; Padhi S; Mohan P; Deshwal S; Sur S; Ghosh M; Agarwal A; Sarin R; Ahmed R; Almel S; Chakraborti B; Raina V; DadiReddy PK; Smruti BK; Rajappa S; Dodagoudar C; Aggarwal S; Singhal M; Joshi A; Kumar R; Kumar A; Mishra DK; Arora N; Karaba A; Sankaran S; Katragadda S; Ghosh A; Veeramachaneni V; Hariharan R; Mannan AU
    Breast Cancer Res Treat; 2018 Jul; 170(1):189-196. PubMed ID: 29470806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.